durapatite has been researched along with sodium phytate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campistol, JM; Canals, AZ; Ferrer, MD; Joubert, PH; Maduell, F; Ojeda, R; Perelló, J; Salcedo, C; Torregrosa, V | 1 |
| Bellasi, A; Bover, J; Bushinsky, D; Chertow, GM; Garg, R; Gillotti, K; Gold, A; Ketteler, M; Padgett, C; Perelló, J; Raggi, P; Rodriguez, M; Salcedo, C; Sinha, S | 1 |
2 trial(s) available for durapatite and sodium phytate
| Article | Year |
|---|---|
A phase 1b randomized, placebo-controlled clinical trial with SNF472 in haemodialysis patients.
Topics: Aged; Calcinosis; Cardiomyopathies; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Durapatite; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Phytic Acid; Placebos; Renal Dialysis | 2019 |
Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis: Results of a Randomized Phase 2b Study.
Topics: Aged; Aortic Valve; Coronary Artery Disease; Disease Progression; Double-Blind Method; Durapatite; Europe; Female; Heart Valve Diseases; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Phytic Acid; Renal Dialysis; Time Factors; Treatment Outcome; United States; Vascular Calcification | 2020 |